Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 7, 2008
JNCI Journal of the National Cancer Institute 2008 100(20):1428-1429; doi:10.1093/jnci/djn375
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/20/1428    most recent
djn375v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schmidt, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, C.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Resistance Revisited: Looking Back at 10 Years of Multidrug Resistance Research

Charlie Schmidt

The first 150 words of the full text of this article appear below.

This is part of an occasional series that recalls some of the stories reported 10 years ago in the News section of the Journal.

In 1998, JNCI published a two-part feature about efforts to overcome multidrug resistance in cancer, which at the time was thought to be governed chiefly by a superfamily of molecular transporters, known as ATP-binding cassette (ABC) proteins. ABC transporters act as efflux pumps, which expel toxins and drugs from a cell. By reversing those transporters in cancer cells—particularly P-glycoprotein (Pgp), which was, and still is, the best-characterized among them—researchers hoped to overcome drug resistance, a primary cause of treatment failure.

A decade later, efforts to reverse Pgp have proven futile, in part because the transport protein is also expressed by healthy tissues—leading to unacceptable side effects when its activity is knocked out. Furthermore, dozens of other ABC transport proteins identified within the last 10 years can . . . [Full Text of this Article]

A New Front

New Approaches

Tackling Single-Drug Resistance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Disease Progression in Some Cancers May Be Due to Low Blood Levels of Targeted Therapies
Rabiya S. Tuma
J Natl Cancer Inst 2008 100: 912-913. [Extract] [Full Text] [PDF]